Cargando…

A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents

BACKGROUND: Adolescents experience higher levels of non-adherence to HIV treatment. Drug concentration in hair promises to be reliable for assessing exposure to antiretroviral (ARV) drugs. Pharmacokinetic modelling can explore utility of drug in hair. We aimed at developing and validating a pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ngara, Bernard, Zvada, Simbarashe, Chawana, Tariro Dianah, Stray-Pedersen, Babill, Nhachi, Charles Fungai Brian, Rusakaniko, Simbarashe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398395/ https://www.ncbi.nlm.nih.gov/pubmed/32746923 http://dx.doi.org/10.1186/s40360-020-00437-y

Ejemplares similares

Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe
por: Ngara, Bernard, et al.
Publicado: (2021)

Evaluating an enhanced adherence intervention among HIV positive adolescents failing atazanavir/ritonavir-based second line antiretroviral treatment at a public health clinic
por: Chawana, Tariro Dianah, et al.
Publicado: (2017)

The prevalence, incidence and risk factors of herpes simplex virus type 2 infection among pregnant Zimbabwean women followed up nine months after childbirth
por: Munjoma, Marshall W, et al.
Publicado: (2010)

CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
por: Dhoro, Milcah, et al.
Publicado: (2015)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
por: Dickinson, Laura, et al.
Publicado: (2009)

Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
por: Hamada, Yohei, et al.
Publicado: (2013)

The burden and risk factors of Sexually Transmitted Infections and Reproductive Tract Infections among pregnant women in Zimbabwe
por: Kurewa, Nyaradzai E, et al.
Publicado: (2010)

Assessing early child development and its association with stunting and schistosome infections in rural Zimbabwean children using the Griffiths Scales of Child Development
por: Mutapi, Francisca, et al.
Publicado: (2021)

Evaluation of transcutaneous bilirubinometer (DRAEGER JM 103) use in Zimbabwean newborn babies
por: Chimhini, Gwendoline Lilly Tanyaradzwa, et al.
Publicado: (2018)

Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2021)

Apolipoprotein B Gene Polymorphisms and Dyslipidemia in HIV Infected Adult Zimbabweans
por: Kodogo, Vitaris, et al.
Publicado: (2016)

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
por: Ganesan, Anuradha, et al.
Publicado: (2009)

Correction to: Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2022)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

The incidence of HIV among women recruited during late pregnancy and followed up for six years after childbirth in Zimbabwe
por: Munjoma, Marshall W, et al.
Publicado: (2010)

Prevalence and associated factors of smoking among secondary school students in Harare Zimbabwe
por: Bandason, Tsitsi, et al.
Publicado: (2010)

Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort
por: Postorino, Maria Concetta, et al.
Publicado: (2017)

Reduced HIV transmission at subsequent pregnancy in a resource-poor setting
por: Gumbo, Felicity Zvanyadza, et al.
Publicado: (2011)

Antenatal HIV-1 RNA load and timing of mother to child transmission; a nested case-control study in a resource poor setting
por: Duri, Kerina, et al.
Publicado: (2010)

Clinical utility of peptide microarrays in the serodiagnosis of neglected tropical diseases in sub-Saharan Africa: protocol for a diagnostic test accuracy systematic review
por: Vengesai, Arthur, et al.
Publicado: (2021)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
por: Squires, Kathleen E., et al.
Publicado: (2011)

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
por: Laker, Eva Agnes Odongpiny, et al.
Publicado: (2019)

Use of Proviral DNA to Investigate Virus Resistance Mutations in HIV-infected Zimbabweans
por: Musingwini, Tutsirai V., et al.
Publicado: (2017)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

Safety and Tolerability of High Dose Atazanavir–Ritonavir and Lopinavir–Ritonavir in Pregnant Women Living with Human Immunodeficiency Virus
por: McLaughlin, Milena M, et al.
Publicado: (2017)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2019)

Prioritizing health system and disease burden factors: an evaluation of the net benefit of transferring health technology interventions to different districts in Zimbabwe
por: Shamu, Shepherd, et al.
Publicado: (2016)

A Characterisation and Profiling of District Health Indicators in Zimbabwe: An Application of Principal Component Analysis in a Data Limited Setting
por: Shamu, Shepherd, et al.
Publicado: (2015)

Atazanavir/ritonavir: QTc prolongation following off-label treatment: case report
Publicado: (2021)

Multiplex peptide microarray profiling of antibody reactivity against neglected tropical diseases derived B-cell epitopes for serodiagnosis in Zimbabwe
por: Vengesai, Arthur, et al.
Publicado: (2022)

Sexual behaviour does not reflect HIV-1 prevalence differences: a comparison study of Zimbabwe and Tanzania
por: Mapingure, Munyaradzi P, et al.
Publicado: (2010)

Validation of a culturally modified short form of the McCarthy Scales of Children’s Abilities in 6 to 8 year old Zimbabwean school children: a cross section study
por: Kandawasvika, Gwendoline Q, et al.
Publicado: (2012)

Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients
por: Avihingsanon, A, et al.
Publicado: (2010)

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
por: Rusconi, Stefano, et al.
Publicado: (2012)

Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study
por: van Lunzen, Jan, et al.
Publicado: (2016)

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice
por: Gantner, Pierre, et al.
Publicado: (2016)

Dried blood spot omega-3 and omega-6 long chain polyunsaturated fatty acid levels in 7–9 year old Zimbabwean children: a cross sectional study
por: Mashavave, Grace, et al.
Publicado: (2016)

Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
por: Smith, Christiana, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2lujf8uvia18996vcnasa98kip